Results

Total Results: 1,494 records

Showing results for "harms".

21. AHRQ Slide Template 2009 (ppt file)
    effectivehealthcare.ahrq.gov/sites/default/files/selecting-evidence.ppt
    January 01, 2010 - Assessing harms can be difficult. … Harms Assessments Harms Assessments Now, we will consider issues related to including observational … Assessing harms can be difficult. … Often the assessment of harms within RCTs is a secondary consideration, the quality and quantity of harms … Using Observational Studies To Assess Harms Using Observational Studies To Assess Harms Observational

22. Comparative Effectiveness Review No. 258_Diagnostic Errors in the Emergency Department: A Systematic Review (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/diagnostic-error-executive-summary.pdf
    August 01, 2023 - , 2.6 million (2.0%) suffer an adverse event as a result, and about 370,000 (0.3%) suffer serious harms … each year this would be over 1,400 diagnostic errors, 500 diagnostic adverse events, and 75 serious harms … All three were conducted at university hospitals, and, for the two studies used to estimate harms, about … Malpractice claims associated with serious misdiagnosis-related harms involved failures of clinical … Together, they accounted for 68 percent (95% CI 66 to 71) of all serious harms from diagnostic error

23. CER 218 Disposition of Comments: Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-218-osteoporosis-disposition-comments.pdf
    April 23, 2019 - as class- specific harms for DMB. … , and Technical Expert Panel harms research priorities. … benefit/”harms” discussion. … treatments with these harms separately. … Most of the information in the draft report on harms, particularly on rare harms, was from observational

24. S23 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/s23.pdf
    October 01, 2007 - of atypical antipsychotics.21 The review summarized 5 RCTs that discussed harms. … Asymmetric Communication of Benefits and Harms Benefits may be presented in relative terms but harms … for both benefits and harms. … for harms). … benefits, and 11% reported only harms.

25. Topic 0552 Low Back Pain NSD FINAL SJ (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND-0651-131114.pdf
    June 20, 2013 - The nominator is also interested in the harms and benefits of the treatment options. … In patients with low back pain, what are the benefits and harms of identifying risk from Nominator: … What are the comparative benefits and harms of different pharmacological therapies for radicular low … What are the comparative benefits and harms of different non-pharmacological, non-invasive therapies … What are the comparative benefits and harms of combinations of therapies (versus single therapies or

26. Therapies for Clinically Localized Prostate Cancer: Evidence Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/prostate-cancer-therapies-summary.pdf
    September 01, 2020 - prostatectomy (RP) may reduce mortality and metastases more than watchful waiting (WW) but causes more harms … Harms were lowest with AM compared with RP or EBR plus AD or AS versus photodynamic therapy. … Associated harms were unclear. … Harms are greater with RP. AM was compared with RP or EBR plus AD in PSA screen–detected CLPC. … However, it may also result in an increase in harms.

27. Layout 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain_executive.pdf
    October 01, 2011 - Key Question Strength of Evidence Conclusion GI and CV harms: Celecoxib High for GI harms vs. nonselective … GI and CV harms: Partially selective NSAIDs GI harms: Moderate for meloxicam and etodolac (fewer trials … GI and CV harms: Nonselective NSAIDs GI harms: High for naproxen, ibuprofen, and diclofenac (consistent … Key Question Strength of Evidence Conclusion GI and CV harms: Nonselective NSAIDs (continued) CV harms … GI and CV harms: Aspirin Moderate for GI and CV harms (many trials, but almost exclusively in patients

28. Pressure-Ulcer-Treatment Executive (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/pressure-ulcer-treatment_executive.pdf
    May 01, 2013 - They were included for the assessment of harms if they reported on harms of treatments for which data … (continued) Harms: Local Wound Applications Dressings and topical therapies Moderate Harms reported … harms by ulcer characteristics. … harms by patient characteristics. … harms by patient care setting.

29. 1. What are the benefits and harms of rhythm control compared to rate control (including newer agents) ? What are the benefits and harms of strict vs more lenient rate control? 2. What are the benefits and harms of different… | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/get-involved/nominated-topics/1-what-are-the-benefits-and-harms-of-rhythm-control-compared-to-rate-control-including-newer-agents-what-are-the-benefits-and-harms-of-strict-vs-more-lenient-rate-control-2-what-are-the-benefits-and-harms-of-different-antico

30. Medical Therapies for Children With Autism Spectrum Disorder—An Update (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/asd-medical-executive-170505.pdf
    May 01, 2017 - High SOE for clinically significant harms associated with risperidone Harms including weight gain … High SOE for clinically significant harms associated with aripiprazole Harms including weight gain … Low SOE for minimal harms No clinically significant harms reported in any study N-acetylcysteine … Low SOE for minimal harms No study reported harms considered clinically important Table B. … Harms reporting varied across studies; some studies amply described how harms were tracked, while others

31. App-F2-Surv-Report-1-Nonopioid-Pharmacol-Chronic-Pain (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-f2-surv-report-1-nonopioid-pharmacol-chronic-pain.xlsx
    May 29, 2025 - Harms of tricyclic antidepressants versus placebo Author, Year Quality Pain Population Drug Class Drug … Harms of pregabalin versus placebo Author, Year Quality Pain Population Drug Class Drug Assessment Time … Harms of pregabalin CR versus IR Author, Year Quality Pain Population Drug Class Drug Assessment Time … Harms of cannabis versus placebo Author, Year Quality Pain Population Drug Assessment Time (Wk) Time … Harms of lidocaine patch versus placebo Author, Year Quality Pain Population Drug Assessment Time (Wk

32. Effective Health Care (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND__0250_05-20-2010.pdf
    January 01, 2010 - What are the benefits and harms of rhythm control compared to rate control (including newer agents)? … What are the benefits and harms of strict versus more lenient rate control? 2. … What are the benefits and harms of different anticoagulation and antiplatelet agents and monitoring … What are the benefits and harms of antiarrhythmic agents for acute conversion of AF to sinus rhythm … What are the benefits and harms of ACEIs, ARBs and statins in the prevention of new AF and progression

33. Making Healthcare Safer IV_Rapid Response_Deprescribing To Reduce Medication Harms in Older Adults (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/mhs-IV-rapid-response-deprescribing.pdf
    February 01, 2024 - Making Healthcare Safer IV_Rapid Response_Deprescribing To Reduce Medication Harms in Older Adults … Making Healthcare Safer IV Deprescribing To Reduce Medication Harms in Older Adults Rapid Response … What are the frequency and severity of harms associated with polypharmacy or potentially inappropriate … We answered Review Questions 1 and 2 by focusing on the harms and patient safety measures or indicators … Making Healthcare Safer IV: Deprescribing To Reduce Medication Harms in Older Adults.

34. Treatment of Depression in Children and Adolescents: A Systematic Review - Evidence Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/Evidence%20Summary_0_0.pdf
    April 01, 2020 - - Evidence Summary Purpose of Review The purpose of the review is to examine the benefits and harms … base, in order to capture the potential for a signal of harms. … With high risk-of-bias studies, the evidence suggests increased risk of harms. … Fourth, psychotherapy studies rarely reported on harms. … No evidence on harms of psychotherapy was identified. References 1.

35. Effective Health Care (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0024_06-09-2008.pdf
    January 01, 2008 - effects of treating older patients with antipsychotics and requests information on the benefits and harms … ), do the typical and atypical antipsychotic drugs differ in benefits (efficacy, effectiveness) or harms … schizophrenia, do the atypical antipsychotic drugs differ in benefits (efficacy, effectiveness) or harms … , do the typical and atypical antipsychotic drugs differ in benefits (efficacy, effectiveness) or harms … review from the EHC Program focus on key long-term, real life effectiveness trials and comparative harms

36. Comparative Effectiveness Review No. 234 Evidence Summary: Management of Primary Headaches in Pregnancy (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-234-headaches-pregnancy-summary.pdf
    November 01, 2020 -  A single primary study provided insufficient (direct) evidence to make conclusions about the harms … The uncertainty about the comparative effectiveness and harms of various treatment options underscores … ; fetal/child harms were not reported. …  No indirect evidence regarding harms of nonpharmacologic interventions in pregnancy was identified … For additional information on harms, we also searched for relevant SRs of interventions in women in

37. What do we know about how evidence of harm and benefit is communicated in other countries? (ppt file)
    effectivehealthcare.ahrq.gov/sites/default/files/communicating_risk_international_king.ppt
    January 01, 2005 - Explicit approach to translation of evidence (but not rating of strength) Explicit description of harms … (not available for review) Approach to translating evidence not described Included description of harms … How does product discuss strength of evidence about benefits and/or harms? … NZGG: HRT—New Information for Women Appropriate Audience Compare Alternatives Benefits and Harms … Pain Guidelines Group: Acute Low Back Pain Appropriate Audience Compare Alternatives Benefits and Harms

38. App-F2-Surv-Report-3-Nonopioid-Pharmacol-Chronic-Pain (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-f2-surv-report-3-nonopioid-pharmacol-chronic-pain.xlsx
    May 29, 2025 - Harms of tricyclic antidepressants versus placebo Author, Year Quality Pain Population Drug Class Drug … Harms of serotonin–norepinephrine reuptake inhibitor versus placebo Author, Year Quality Pain Population … Harms of pregabalin versus placebo Author, Year Quality Pain Population Drug Class Drug Assessment Time … Harms of pregabalin CR versus IR Author, Year Quality Pain Population Drug Class Drug Assessment Time … Harms of cannabis versus placebo Author, Year Quality Pain Population Drug Assessment Time (Wk) Time

39. Evidence Summary: Comparative Effectiveness Review No. 238: Cervical Ripening (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/cer-238-cervical-ripening-evidence-summary.pdf
    March 01, 2021 - and Purpose The purpose of this review is to assess the comparative effectiveness and potential harms … majority of the evidence (22 RCTs, 1 cohort study) pertained to the comparative effectiveness and harms … Primary fetal harms outcomes Key Question Intervention Outcome Findingsa Studies Incidence Relative … Differences in rare harms, such as hypoxic-ischemic encephalopathy, would require much larger studies … , although not all such harms were adequately studied.

40. CER 229 Evidence Summary: Opioid Treatments for Chronic Pain (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/cer-229-opioid-treatments-chronic-pain-evidence-summary.pdf
    April 01, 2020 - harms, infections, cardiovascular events, cognitive harms, and psychological harms (e.g., depression … harms, infections, cardiovascular events, cognitive harms, and mental health harms (e.g., depression … harms, infections, cardiovascular events, cognitive harms, and mental health harms (e.g., depression … Harms of opioids vs. … Harms of opioids vs.